Search by Drug Name or NDC

    NDC 61480-0105-03 PSORIASIS 3; 1; 4; 2; 4 [hp_X]/237mL; [hp_X]/237mL; [hp_X]/237mL; [hp_X]/237mL; [hp_X]/237mL Details

    PSORIASIS 3; 1; 4; 2; 4 [hp_X]/237mL; [hp_X]/237mL; [hp_X]/237mL; [hp_X]/237mL; [hp_X]/237mL

    PSORIASIS is a ORAL LIQUID in the HUMAN OTC DRUG category. It is labeled and distributed by PLYMOUTH HEALTHCARE PRODUCTS LLC. The primary component is NICKEL SULFATE HEXAHYDRATE; POTASSIUM BROMIDE; POTASSIUM SULFATE; SODIUM BROMIDE; ZINC BROMIDE.

    Product Information

    NDC 61480-0105
    Product ID 61480-105_d44a6335-b07b-6659-e053-2995a90a1eee
    Associated GPIs
    GCN Sequence Number n/a
    GCN Sequence Number Description n/a
    HIC3 n/a
    HIC3 Description n/a
    GCN n/a
    HICL Sequence Number n/a
    HICL Sequence Number Description n/a
    Brand/Generic n/a
    Proprietary Name PSORIASIS
    Proprietary Name Suffix n/a
    Non-Proprietary Name Niccolum Sulphuricum, Natrum Bromatum, Zincum Bromatum, Kali Bromatum, Kali Sulphuricum.
    Product Type HUMAN OTC DRUG
    Dosage Form LIQUID
    Route ORAL
    Active Ingredient Strength 3; 1; 4; 2; 4
    Active Ingredient Units [hp_X]/237mL; [hp_X]/237mL; [hp_X]/237mL; [hp_X]/237mL; [hp_X]/237mL
    Substance Name NICKEL SULFATE HEXAHYDRATE; POTASSIUM BROMIDE; POTASSIUM SULFATE; SODIUM BROMIDE; ZINC BROMIDE
    Labeler Name PLYMOUTH HEALTHCARE PRODUCTS LLC
    Pharmaceutical Class Copper Absorption Inhibitor [EPC], Decreased Copper Ion Absorption [PE], Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Osmotic Activity [MoA], Osmotic Laxative [EPC]
    DEA Schedule n/a
    Marketing Category UNAPPROVED HOMEOPATHIC
    Application Number n/a
    Listing Certified Through 2024-12-31

    Package

    NDC 61480-0105-03 (61480010503)

    NDC Package Code 61480-105-03
    Billing NDC 61480010503
    Package 237 mL in 1 BOTTLE (61480-105-03)
    Marketing Start Date 2016-12-12
    NDC Exclude Flag N
    Pricing Information N/A

    Standard Product Labeling (SPL)/Prescribing Information SPL 7ad9e8ac-c8a3-4cab-8ab2-15feaf4bd3dc Details

    Revised: 12/2021